|
Jun 24
|
Carisma Therapeutics, OrthoCellix enter definitive merger agreement
|
|
Jun 23
|
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
|
|
Jun 17
|
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment
|
|
Jun 16
|
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
|
|
Jun 5
|
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
|
|
Feb 13
|
Why Ocugen (OCGN) Is Advancing Today
|
|
Feb 12
|
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
|